BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,037 filers reported holding BAXTER INTL INC in Q1 2015. The put-call ratio across all filers is 0.65 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2015 | $4,917,000 | -61.8% | 149,688 | -18.7% | 0.06% | -57.9% |
| Q2 2015 | $12,873,000 | +1.9% | 184,080 | -0.2% | 0.13% | +6.4% |
| Q1 2015 | $12,638,000 | +99.9% | 184,502 | +113.9% | 0.12% | +56.2% |
| Q4 2014 | $6,322,000 | -36.6% | 86,255 | -37.9% | 0.08% | -15.8% |
| Q3 2014 | $9,968,000 | +7.8% | 138,895 | +8.6% | 0.10% | +11.8% |
| Q2 2014 | $9,250,000 | +4.7% | 127,940 | +6.5% | 0.08% | -1.2% |
| Q1 2014 | $8,837,000 | +33.7% | 120,100 | +26.3% | 0.09% | +32.3% |
| Q4 2013 | $6,611,000 | +15.8% | 95,060 | +9.3% | 0.06% | +3.2% |
| Q3 2013 | $5,711,000 | – | 86,940 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tavio Capital LLC | 68,405 | $5,890,000 | 7.81% |
| Iron Triangle Partners LP | 330,000 | $28,413,000 | 7.16% |
| Veritas Asset Management LLP | 8,942,428 | $769,943,000 | 5.64% |
| TSFG, LLC | 93,405 | $8,042,000 | 5.31% |
| GENERATION INVESTMENT MANAGEMENT LLP | 10,606,094 | $913,185,000 | 5.27% |
| Third Point | 4,000,000 | $344,400,000 | 4.72% |
| Avidity Partners Management LP | 800,900 | $68,957,000 | 4.42% |
| Palmer Knight Co | 62,275 | $5,362,000 | 4.17% |
| Eos Focused Equity Management, L.P. | 36,786 | $3,167,000 | 3.70% |
| Dundas Partners LLP | 196,133 | $16,887,000 | 3.69% |